Unosi

• KLINIČKE VODILJE ZA TRETMAN HIV-a I AIDS- (2021)

  Z. Čardaklija, D. Galić, N. Grubiša, V. Hadžiosmanović, R. Jahić, L. Jandrić, A. Kurtović, V. Marčinko, V. Martinović, S. Ritan, S. Skočibušić, S. Stanić, A. Verhaz, A. Verhaz, KLINIČKE VODILJE ZA TRETMAN HIV-a I AIDS-, Udruženje „Partnerstvo za zdravlje“, Sarajevo, 2021

• REGISTAR LIJEKOVA REPUBLIKE SRPSKE SA OSNOVAMA FARMAKOTERAPIJE (2007)

  S. Stojisavljević Šatara, S. Dobrić, S. Milovanović, S. Vladimirov, N. Grubiša, V. Marković-Peković, B. Tubić, REGISTAR LIJEKOVA REPUBLIKE SRPSKE SA OSNOVAMA FARMAKOTERAPIJE, AGENCIJA ZA LIJEKOVE REPUBLIKE SRPSKE, 2007

• ATC klasifikacija lijekova i praćenje njihove upotrebe metodologijom sa DDD jedinicama za lijekove registrovane u Republici Srpskoj (2007)

  R. Škrbić, V. Marković Peković, S. Stoisavljević-Šatara, N. Grubiša, B. Tubić, ATC klasifikacija lijekova i praćenje njihove upotrebe metodologijom sa DDD jedinicama za lijekove registrovane u Republici Srpskoj, Agencija za lijekove Republike Srpske u saradnji sa Zavodom za farmakologiju, toksikologiju i kliničku farmakologiju Medicinski fakultet Banja Luka, 2007

• The pharmaceutical sector in the Republic of Srpska, Bosnia and Herzegovina (2009-01)

  V. Marković Peković, R. Škrbić, N. Grubiša, The pharmaceutical sector in the Republic of Srpska, Bosnia and Herzegovina, Eurohealth, Vol. 15, No. 1, pp. 23 - 26, Jan, 2009

• Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior (2012-10)

  V. Marković Peković, N. Grubiša, Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 21, No. 10, pp. 1130 - 1133, Oct, 2012

• Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications (2017-06)

  V. Marković Peković, N. Grubiša, J. Burger, L. Bojanić, B. Godman, Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications, Journal of Research in Pharmacy Practice, Vol. 6, pp. 120 - 125, Jun, 2017

• Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study. (2018-06)

  U. Glamočlija, B. Tubić, M. Kondža, A. Zolak, N. Grubiša, Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study., CROATIAN MEDICAL JOURNAL, Vol. 59, No. 3, pp. 124 - 131, Jun, 2018

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019

• The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

  E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021

• Initiatives to reduce nonprescription sales and dispensing of antibiotics; findings and implications (2017-11)

  V. Marković Peković, N. Grubiša, L. Bojanić, B. Godman, Initiatives to reduce nonprescription sales and dispensing of antibiotics; findings and implications, Abstract Book, pp. 65 - 65, Nov, 2017